Frequently Asked Questions (FAQs)

ORMALVI (dichlorphenamide) tablets

ORMALVI is indicated for the treatment of hyperkalemic periodic paralysis, hypokalemic periodic paralysis and related variants.1 It is a carbonic anhydrase inhibitor, however the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with Primary Periodic Paralysis is unknown.1

ORMALVI is the same proven dichlorphenamide as KEVEYIS,2 accompanied by Cycle VitaTM, a dedicated support platform which may help your eligible** patients live with confidence in managing their condition.

Find out more about Cycle Vita

ORMALVI is the same proven dichlorphenamide, accompanied by Cycle Vita, a dedicated support platform which may help your eligible** patients live with confidence in managing their condition.

Find out more about Cycle Vita

For a patient diagnosed with Primary Periodic Paralysis you can print and send a completed enrollment form to Cycle Vita at hello@cyclevita.life or fax it to them at +1 (888) 385-8482.

Download enrollment form

Primary Periodic Paralysis diagnosis

Genetic testing is recommended as the first diagnostic step where there is a high clinical likelihood of a Primary Periodic Paralysis diagnosis.2

Find out more

Only 60% to 70% of patients with Primary Periodic Paralysis receive a positive genetic test.2

For the remaining 30% to 40% of patients with Primary Periodic Paralysis, diagnosis can be based upon clinical presentation, potassium levels in your blood during attacks, and pattern abnormalities on long exercise testing.2

If a genetic test comes back negative, one or more of the following tests could be utilized to help reach a diagnosis or rule out Primary Periodic Paralysis:

  • Electrocardiogram (ECG/EKG)
  • Electromyography (EMG)
  • Compound muscle action potential (CMAP)

Patient support

Cycle Vita is our dedicated hub support program, which delivers product support** at every step.

Find out more

As soon as Cycle Vita receives a completed enrollment form, we can provide individualized support to eligible** patients, such as access to treatment, financial and pharmacy support, as well as clinical education and medication administration support. We will reach out to you and your patient to take the next steps.

Find out more

The Bridge Program is a free supply of ORMALVI that allows diagnosed patients to begin therapy immediately while Cycle Vita secures appropriate Benefit Verification and Prior Authorization. The Bridge Program may also be requested for existing patients who are temporarily experiencing disruption in therapy due to insurance coverage.

If your patient’s insurance situation changes, the patient must notify Cycle Vita immediately at +1 (888) 360-8482.

Find out more

Commercially insured eligible patients who have been prescribed ORMALVI may pay as little as $0 in co-pay.**

To find out more about eligibility criteria please contact Cycle Vita on +1 (888) 360-8482.

Find out more

The Cycle Vita team are just a phone call away. You can expect to hear from two types of people at Cycle Vita:

Check Icon

Access Specialists – help your patients access ORMALVI through enrollment, financial and pharmacy support**

Check Icon

Clinical Specialists – provide clinical education, clinical support and medication administration support**

When your patient is prescribed ORMALVI they can expect financial, logistics and educational support, including:

Check Icon

Bridge Program**: A free supply of ORMALVI that allows diagnosed patients to begin therapy immediately while Cycle Vita secures appropriate Benefit Verification and Prior Authorization. The Bridge Program may also be requested for existing patients who are temporarily experiencing disruption in therapy due to insurance coverage.

Check Icon

Co-pay Program**: On ORMALVI, commercially insured eligible patients may pay as little as $0.

Check Icon

Continuous Clinical Product Support: Cycle Vita provides patients with product support to help manage every aspect of the ORMALVI therapeutic routine, such as clinical education and onboarding onto dichlorphenamide.

Check Icon

Patient Nutrition Program**: On-going personal guidance and education for patients through the duration of therapy. Monthly calls with patients can be up to 30-minutes and are tailored to their type of PPP and any known triggers, to reinforce their clinic's nutrition plan.

Check Icon

Patient Community Support: Finally reaching a diagnosis can be a relieving experience for patients, but it can be a challenging time too. Through Cycle Vita, we can introduce your patients to the Periodic Paralysis Association (PPA), a non-profit charitable corporation founded to foster awareness of periodic paralysis, promote science-based information regarding this class of disorder, and champion the interests of the Periodic Paralysis Community.

Find out more

Getting started

Complete an ORMALVI enrollment form and either email it to our Cycle Vita team at hello@cyclevita.life or fax it to them at + 1 (888) 385-8482.

Once they receive the form, our expert team will take care of all the details so your patients can get started on their treatment as soon as possible.

Please use the enrollment form rather than your own prescription form to avoid delays.  You can use the Rx Checklist to help you complete the enrollment form correctly. And remember to specify dispense as written (DAW) on every enrollment form to ensure that your patients receive ORMALVI and the support available through Cycle Vita.

Rx Checklist
A friendly, familiar team is waiting here at Cycle Vita, for you, at every step.
Cycle Vita Logo With Strapline
Cycle Vita Logo With Strapline
A friendly, familiar team is waiting here at Cycle Vita, for you, at every step.

+1 (888) 360-8482

References

  1. ORMALVI (dichlorphenamide). Prescribing Information. Cycle Pharmaceuticals Ltd.
  2. Statland, J., et al (2017). Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle & Nerve, [online] 57(4), pp.522–530. Available at:: https://doi.org/10.1002/mus.26009 [Accessed 1 Nov. 2023].

*KEVEYIS® and its associated logo is a trademark owned by or licensed to Xeris Pharmaceuticals, Inc.

**Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.